Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Price Target at $13.43

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $13.4286.

A number of research analysts have issued reports on OPRX shares. UBS Group set a $10.00 target price on shares of OptimizeRx in a report on Wednesday, May 13th. Stephens dropped their target price on shares of OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, May 13th. Zacks Research cut shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Weiss Ratings cut shares of OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, May 14th. Finally, Roth Mkm dropped their target price on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in OptimizeRx by 15.0% during the third quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after acquiring an additional 138,224 shares during the last quarter. Royce & Associates LP raised its position in OptimizeRx by 0.7% during the fourth quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock worth $8,362,000 after acquiring an additional 4,700 shares during the last quarter. Kennedy Capital Management LLC raised its position in OptimizeRx by 42.8% during the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after acquiring an additional 202,446 shares during the last quarter. Rice Hall James & Associates LLC increased its stake in shares of OptimizeRx by 1.9% during the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after purchasing an additional 11,247 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of OptimizeRx by 22.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after purchasing an additional 102,661 shares during the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Trading Down 0.8%

NASDAQ OPRX opened at $5.28 on Friday. The stock has a market capitalization of $99.05 million, a P/E ratio of 15.09 and a beta of 1.13. OptimizeRx has a 52-week low of $4.57 and a 52-week high of $22.25. The firm has a 50-day moving average price of $5.79 and a 200 day moving average price of $8.79. The company has a quick ratio of 5.37, a current ratio of 5.37 and a debt-to-equity ratio of 0.16.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. The firm had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. Equities research analysts expect that OptimizeRx will post 0.51 EPS for the current year.

OptimizeRx declared that its Board of Directors has initiated a share buyback plan on Thursday, March 5th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.